Chengyong Zhou1, Baochun Sun2. 1. Department of Otolaryngology the First Affiliated Hospital of PLA General Hospital, Beijing 100048, China. Electronic address: chengyongzhou72@126.com. 2. Department of Otolaryngology the First Affiliated Hospital of PLA General Hospital, Beijing 100048, China.
Abstract
OBJECTIVE: This study aimed to investigate the correlation between aldehyde dehydrogenase 1 (ALDH1)-positive head and neck squamous cell carcinomas (HNSCC) and clinicopathological features and its effect on survival. A meta-analysis based on published studies was conducted to accurately evaluate the association between the presence of cancer stem cells (CSCs) in clinical samples and clinical outcome. METHODS: A search in the PubMed, EMBASE, and Wanfang databases (up to May 1, 2014) was conducted. Publications assessing the clinical or prognostic significance of ALDH1 expression in HNSCC were identified and reviewed until May 1, 2014. A meta-analysis was performed to clarify the association between ALDH1 expression and clinical outcomes. RESULTS: A total of 9 publications satisfied the criteria and comprised 749 cases. ALDH1 expression was not significantly associated with tumor T stage [I+II vs. III+IV; odds ratio (OR)=1.23, 95% confidence interval (CI)=0.70-2.15, P=0.48]. However, in the identified studies, ALDH1 expression was highly correlated with tumor differentiation (G1+G2 vs. G3; OR=3.30, 95% CI=1.92-5.67, P<0.001), lymph node metastasis (OR=4.07, 95% CI=1.18-14.10, P=0.03), decreased overall survival [relative risk (RR)=1.84, 95% CI=1.43-2.36, P<0.0001], and decreased disease-free survival (RR=2.34, 95% CI=1.37-4.00, P=0.002). CONCLUSION: ALDH1-positive HNSCC patients had worse prognosis, which was associated with common clinicopathological features and poor prognostic factors.
OBJECTIVE: This study aimed to investigate the correlation between aldehyde dehydrogenase 1 (ALDH1)-positive head and neck squamous cell carcinomas (HNSCC) and clinicopathological features and its effect on survival. A meta-analysis based on published studies was conducted to accurately evaluate the association between the presence of cancer stem cells (CSCs) in clinical samples and clinical outcome. METHODS: A search in the PubMed, EMBASE, and Wanfang databases (up to May 1, 2014) was conducted. Publications assessing the clinical or prognostic significance of ALDH1 expression in HNSCC were identified and reviewed until May 1, 2014. A meta-analysis was performed to clarify the association between ALDH1 expression and clinical outcomes. RESULTS: A total of 9 publications satisfied the criteria and comprised 749 cases. ALDH1 expression was not significantly associated with tumor T stage [I+II vs. III+IV; odds ratio (OR)=1.23, 95% confidence interval (CI)=0.70-2.15, P=0.48]. However, in the identified studies, ALDH1 expression was highly correlated with tumor differentiation (G1+G2 vs. G3; OR=3.30, 95% CI=1.92-5.67, P<0.001), lymph node metastasis (OR=4.07, 95% CI=1.18-14.10, P=0.03), decreased overall survival [relative risk (RR)=1.84, 95% CI=1.43-2.36, P<0.0001], and decreased disease-free survival (RR=2.34, 95% CI=1.37-4.00, P=0.002). CONCLUSION:ALDH1-positive HNSCC patients had worse prognosis, which was associated with common clinicopathological features and poor prognostic factors.
Authors: Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García Journal: Cancers (Basel) Date: 2022-08-08 Impact factor: 6.575
Authors: M Martín; A Hinojar; L Cerezo; J García; M Lopez; J Prada; A Marín; C Gamallo Journal: Clin Transl Oncol Date: 2015-11-16 Impact factor: 3.405
Authors: Elizabeth A Stanford; Alejandra Ramirez-Cardenas; Zhongyan Wang; Olga Novikov; Khalid Alamoud; Petros Koutrakis; Joseph P Mizgerd; Caroline A Genco; Maria Kukuruzinska; Stefano Monti; Manish V Bais; David H Sherr Journal: Mol Cancer Res Date: 2016-04-29 Impact factor: 5.852
Authors: Kariem Sharaf; Axel Lechner; Stefan P Haider; Robert Wiebringhaus; Christoph Walz; Gisela Kranz; Martin Canis; Frank Haubner; Olivier Gires; Philipp Baumeister Journal: Curr Oncol Date: 2021-07-19 Impact factor: 3.677